Changeset 1510 for qrda/C0Q/trunk


Ignore:
Timestamp:
Aug 6, 2012, 2:24:18 PM (12 years ago)
Author:
Sam Habiel
Message:

Added a key on the B index of the C0Q Quality Measures file to help with a data transport issue; besides being the right thing to do.

Location:
qrda/C0Q/trunk/kids
Files:
1 added
1 deleted
1 edited

Legend:

Unmodified
Added
Removed
  • qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID

    r1508 r1510  
    1 KIDS Distribution saved on Aug 03, 2012@17:09:59
     1KIDS Distribution saved on Aug 06, 2012@11:32:48
    22QUALITY MEASURES 1.0 PATCH 3
    33**KIDS**:C0Q*1.0*3^
     
    66C0Q*1.0*3
    77"BLD",7936,0)
    8 C0Q*1.0*3^QUALITY MEASURES^0^3120803^y
     8C0Q*1.0*3^QUALITY MEASURES^0^3120806^y
    99"BLD",7936,1,0)
    1010^^155^155^3120803^
     
    328328
    329329"BLD",7936,6.3)
    330 11
     33012
    331331"BLD",7936,"ABPKG")
    332332n
     
    441441"DATA",1130580001.101,4,6,3,0)
    442442using a certified/qualified electronic health record (EHR)
    443 "DATA",1130580001.101,4,7)
    444 ^^^^
    445443"DATA",1130580001.101,6,0)
    446444PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52
     
    463461"DATA",1130580001.101,6,6,5,0)
    464462or provide an advance care plan.
    465 "DATA",1130580001.101,6,7)
    466 ^^^^
    467463"DATA",1130580001.101,7,0)
    468464PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53
     
    481477"DATA",1130580001.101,7,6,3,0)
    482478absence of urinary incontinence within 12 months
    483 "DATA",1130580001.101,7,7)
    484 ^^^^
    485479"DATA",1130580001.101,12,0)
    486480MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8
     
    515509"DATA",1130580001.101,14,6,3,0)
    516510within 12 months before the end of the measurement period
    517 "DATA",1130580001.101,14,7)
    518 ^^^^
    519511"DATA",1130580001.101,16,0)
    520512PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55
     
    531523"DATA",1130580001.101,16,6,2,0)
    532524ed for unhealthy alcohol use using a systematic method within 24 months
    533 "DATA",1130580001.101,16,7)
    534 ^^^^
    535525"DATA",1130580001.101,23,0)
    536 MU HOS NQF 0495^^
     526MU HOS NQF 0495
    537527"DATA",1130580001.101,23,1)
    538528ED THROUGHPUT ARRIVAL TO DEPARTURE
     
    550540NQF0495^^^^^^88^165
    551541"DATA",1130580001.101,24,0)
    552 MU HOS NQF 0497^^
     542MU HOS NQF 0497
    553543"DATA",1130580001.101,24,1)
    554544ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
     
    566556NQF0497^^^^^^90^168
    567557"DATA",1130580001.101,25,0)
    568 MU HOS NQF 0435^^
     558MU HOS NQF 0435
    569559"DATA",1130580001.101,25,1)
    570560Ischemic stroke.Discharge on anti-thrombotics 
     
    580570NQF0435^^^^^^114^115
    581571"DATA",1130580001.101,26,0)
    582 MU HOS NQF 0436^^
     572MU HOS NQF 0436
    583573"DATA",1130580001.101,26,1)
    584574 Ischemic stroke.Anticoagulation for A-fib/flutter
     
    594584NQF0436^^^^^^116^117
    595585"DATA",1130580001.101,27,0)
    596 MU HOS NQF 0437^^
     586MU HOS NQF 0437
    597587"DATA",1130580001.101,27,1)
    598588 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
     
    610600NQF0437^^^^^^119^118
    611601"DATA",1130580001.101,28,0)
    612 MU HOS NQF 0438^^
     602MU HOS NQF 0438
    613603"DATA",1130580001.101,28,1)
    614604Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
     
    624614NQF0438^^^^^^120^121
    625615"DATA",1130580001.101,29,0)
    626 MU HOS NQF 0439^^
     616MU HOS NQF 0439
    627617"DATA",1130580001.101,29,1)
    628618Ischemic stroke.Discharge on statins
     
    640630NQF0439^^^^^^122^123
    641631"DATA",1130580001.101,30,0)
    642 MU HOS NQF 0440^^
     632MU HOS NQF 0440
    643633"DATA",1130580001.101,30,1)
    644634Ischemic or hemorrhagic stroke.Stroke education
     
    660650NQF0440^^^^^^124^125
    661651"DATA",1130580001.101,31,0)
    662 MU HOS NQF 0441^^
     652MU HOS NQF 0441
    663653"DATA",1130580001.101,31,1)
    664654Ischemic or hemorrhagic stroke.Rehabilitation assessment
     
    674664NQF0441^^^^^^126^127
    675665"DATA",1130580001.101,32,0)
    676 MU HOS NQF 0371^^
     666MU HOS NQF 0371
    677667"DATA",1130580001.101,32,1)
    678668VTE prophylaxis within 24 hours of arrival 
     
    692682NQF0371^^^^^^69^67
    693683"DATA",1130580001.101,33,0)
    694 MU HOS NQF 0372^^
     684MU HOS NQF 0372
    695685"DATA",1130580001.101,33,1)
    696686ICU VTE prophylaxis 
     
    712702NQF0372^^^^^^128^71
    713703"DATA",1130580001.101,34,0)
    714 MU HOS NQF 0373^^
     704MU HOS NQF 0373
    715705"DATA",1130580001.101,34,1)
    716706Anticoagulation overlap therapy 
     
    738728NQF0373^^^^^^129^144
    739729"DATA",1130580001.101,35,0)
    740 MU HOS NQF 0374^^
     730MU HOS NQF 0374
    741731"DATA",1130580001.101,35,1)
    742732Platelet monitoring on unfractionated heparin
     
    768758NQF0374^^^^^^145^146
    769759"DATA",1130580001.101,36,0)
    770 MU HOS NQF 0375^^
     760MU HOS NQF 0375
    771761"DATA",1130580001.101,36,1)
    772762VTE discharge instructions
     
    800790NQF0375^^^^^^147^156
    801791"DATA",1130580001.101,37,0)
    802 MU HOS NQF 0376^^
     792MU HOS NQF 0376
    803793"DATA",1130580001.101,37,1)
    804794Incidence of potentially preventable VTE
     
    908898NQF0041^^^^^^242^243
    909899"DATA",1130580001.101,43,0)
    910 MU EP NQF 0024^^
     900MU EP NQF 0024
    911901"DATA",1130580001.101,43,1)
    912902NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL)
     
    968958combination rates.
    969959"DATA",1130580001.101,44,7)
    970 NQF0038^^^^
     960NQF0038
    971961"DATA",1130580001.101,45,0)
    972962MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2
     
    10361026prescribed ACE inhibitor or ARB therapy
    10371027"DATA",1130580001.101,48,7)
    1038 NQF0081^^^^
     1028NQF0081
    10391029"DATA",1130580001.101,49,0)
    10401030MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6
     
    10701060mammogram to screen for breast cancer
    10711061"DATA",1130580001.101,50,7)
    1072 NQF0031^^^^
     1062NQF0031
    10731063"DATA",1130580001.101,51,0)
    10741064MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10
     
    10861076colorectal cancer.
    10871077"DATA",1130580001.101,51,7)
    1088 NQF0034^^^^
     1078NQF0034
    10891079"DATA",1130580001.101,52,0)
    1090 MU EP NQF 0067^^
     1080MU EP NQF 0067
    10911081"DATA",1130580001.101,52,1)
    10921082Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
     
    11001090diagnosis of CAD who were prescribed oral antiplatelet therapy.
    11011091"DATA",1130580001.101,52,7)
    1102 NQF0067^^^^
     1092NQF0067
    11031093"DATA",1130580001.101,53,0)
    1104 MU EP NQF 0083^^
     1094MU EP NQF 0083
    11051095"DATA",1130580001.101,53,1)
    11061096Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
     
    11161106prescribed beta-blocker therapy
    11171107"DATA",1130580001.101,53,7)
    1118 NQF0083^^^^
     1108NQF0083
    11191109"DATA",1130580001.101,54,0)
    1120 MU EP NQF 0105^^
     1110MU EP NQF 0105
    11211111"DATA",1130580001.101,54,1)
    11221112Anti-depressant medication management:  (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment 
     
    11341124antidepressant medication treatment.
    11351125"DATA",1130580001.101,54,7)
    1136 NQF0105^^^^
     1126NQF0105
    11371127"DATA",1130580001.101,55,0)
    1138 MU EP NQF 0086^^
     1128MU EP NQF 0086
    11391129"DATA",1130580001.101,55,1)
    11401130Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
     
    11521142visits within 12 months.
    11531143"DATA",1130580001.101,55,7)
    1154 NQF0086^^^^
     1144NQF0086
    11551145"DATA",1130580001.101,56,0)
    1156 MU EP NQF 0088^^
     1146MU EP NQF 0088
    11571147"DATA",1130580001.101,56,1)
    11581148Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
     
    11721162one or more office visits within 12 months.
    11731163"DATA",1130580001.101,56,7)
    1174 NQF0088^^^^
     1164NQF0088
    11751165"DATA",1130580001.101,57,0)
    1176 MU EP NQF 0089^^
     1166MU EP NQF 0089
    11771167"DATA",1130580001.101,57,1)
    11781168Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
     
    11941184within 12 months.
    11951185"DATA",1130580001.101,57,7)
    1196 NQF0089^^^^
     1186NQF0089
    11971187"DATA",1130580001.101,58,0)
    1198 MU EP NQF 0047^^
     1188MU EP NQF 0047
    11991189"DATA",1130580001.101,58,1)
    12001190Asthma Pharmacologic Therapy
     
    12121202corticosteroid) or an acceptable alternative treatment
    12131203"DATA",1130580001.101,58,7)
    1214 NQF0047^^^^
     1204NQF0047
    12151205"DATA",1130580001.101,59,0)
    1216 MU EP NQF 0001^^
     1206MU EP NQF 0001
    12171207"DATA",1130580001.101,59,1)
    12181208Asthma Assessment
     
    12321222symptoms.
    12331223"DATA",1130580001.101,59,7)
    1234 NQF0001^^^^
     1224NQF0001
    12351225"DATA",1130580001.101,60,0)
    1236 MU EP NQF 0002^^
     1226MU EP NQF 0002
    12371227"DATA",1130580001.101,60,1)
    12381228Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
     
    12501240reporting period.
    12511241"DATA",1130580001.101,60,7)
    1252 NQF0002^^^^
     1242NQF0002
    12531243"DATA",1130580001.101,61,0)
    1254 MU EP NQF 0385^^
     1244MU EP NQF 0385
    12551245"DATA",1130580001.101,61,1)
    12561246Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
     
    12681258received adjuvant chemotherapy within the 12-month reporting period
    12691259"DATA",1130580001.101,61,7)
    1270 NQF0385^^^^
     1260NQF0385
    12711261"DATA",1130580001.101,62,0)
    1272 MU EP NQF 0389^^
     1262MU EP NQF 0389
    12731263"DATA",1130580001.101,62,1)
    12741264Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
     
    12881278any time since diagnosis of prostate cancer.
    12891279"DATA",1130580001.101,62,7)
    1290 NQF0389^^^^
     1280NQF0389
    12911281"DATA",1130580001.101,63,0)
    1292 MU EP NQF 0027^^
     1282MU EP NQF 0027
    12931283"DATA",1130580001.101,63,1)
    12941284Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
     
    13081298cessation medications, methods or strategies
    13091299"DATA",1130580001.101,63,7)
    1310 NQF0027^^^^
     1300NQF0027
    13111301"DATA",1130580001.101,64,0)
    1312 MU EP NQF 0055^^
     1302MU EP NQF 0055
    13131303"DATA",1130580001.101,64,1)
    13141304Diabetes: Eye Exam
     
    13241314exam (no evidence of retinopathy) by an eye care professional
    13251315"DATA",1130580001.101,64,7)
    1326 NQF0055^^^^
     1316NQF0055
    13271317"DATA",1130580001.101,65,0)
    1328 MU EP NQF 0062^^
     1318MU EP NQF 0062
    13291319"DATA",1130580001.101,65,1)
    13301320Diabetes: Urine Screening
     
    13401330nephropathy.
    13411331"DATA",1130580001.101,65,7)
    1342 NQF0062^^^^
     1332NQF0062
    13431333"DATA",1130580001.101,66,0)
    1344 MU EP NQF 0056^^
     1334MU EP NQF 0056
    13451335"DATA",1130580001.101,66,1)
    13461336Diabetes:  Foot Exam
     
    13561346with monofilament, or pulse exam).
    13571347"DATA",1130580001.101,66,7)
    1358 NQF0056^^^^
     1348NQF0056
    13591349"DATA",1130580001.101,67,0)
    1360 MU EP NQF 0074^^
     1350MU EP NQF 0074
    13611351"DATA",1130580001.101,67,1)
    13621352Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
     
    13721362on current ACC/AHA guidelines).
    13731363"DATA",1130580001.101,67,7)
    1374 NQF0074^^^^
     1364NQF0074
    13751365"DATA",1130580001.101,68,0)
    1376 MU EP NQF 0084^^
     1366MU EP NQF 0084
    13771367"DATA",1130580001.101,68,1)
    13781368Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
     
    13881378who were prescribed warfarin therapy.
    13891379"DATA",1130580001.101,68,7)
    1390 NQF0084^^^^
     1380NQF0084
    13911381"DATA",1130580001.101,69,0)
    1392 MU EP NQF 0073^^
     1382MU EP NQF 0073
    13931383"DATA",1130580001.101,69,1)
    13941384Ischemic Vascular Disease (IVD):  Blood Pressure Management
     
    14201410(<140/90 mmHg).
    14211411"DATA",1130580001.101,69,7)
    1422 NQF0073^^^^
     1412NQF0073
    14231413"DATA",1130580001.101,70,0)
    1424 MU EP NQF 0068^^
     1414MU EP NQF 0068
    14251415"DATA",1130580001.101,70,1)
    14261416Ischemic Vascular Disease (IVD):  Use of Aspirin or Another Antithrombotic
     
    14461436another antithrombotic during the measurement year
    14471437"DATA",1130580001.101,70,7)
    1448 NQF0068^^^^
     1438NQF0068
    14491439"DATA",1130580001.101,71,0)
    1450 MU EP NQF 0004^^
     1440MU EP NQF 0004
    14511441"DATA",1130580001.101,71,1)
    14521442 Initiation and Engagement of Alcohol and Other Drug  Dependence Treatment:(a)Initiation,(b)Engagement
     
    14681458services with an AOD diagnosis within 30 days of the initiation visit.
    14691459"DATA",1130580001.101,71,7)
    1470 NQF0004^^^^
     1460NQF0004
    14711461"DATA",1130580001.101,72,0)
    1472 MU EP NQF 0012^^
     1462MU EP NQF 0012
    14731463"DATA",1130580001.101,72,1)
    14741464Prenatal Care:  Screening for Human Immunodeficiency Virus (HIV)
     
    14841474second prenatal care visit.
    14851475"DATA",1130580001.101,72,7)
    1486 NQF0012^^^^
     1476NQF0012
    14871477"DATA",1130580001.101,73,0)
    1488 MU EP NQF 0014^^
     1478MU EP NQF 0014
    14891479"DATA",1130580001.101,73,1)
    14901480Prenatal Care:  Anti-D Immune Globulin
     
    15001490immune globulin at 26-30 weeks gestation.
    15011491"DATA",1130580001.101,73,7)
    1502 NQD0014^^^^
     1492NQD0014
    15031493"DATA",1130580001.101,74,0)
    1504 MU EP NQF 0018^^
     1494MU EP NQF 0018
    15051495"DATA",1130580001.101,74,1)
    15061496Controlling High Blood Pressure
     
    15161506the measurement year
    15171507"DATA",1130580001.101,74,7)
    1518 NQF0018^^^^
     1508NQF0018
    15191509"DATA",1130580001.101,75,0)
    1520 MU EP NQF 0032^^
     1510MU EP NQF 0032
    15211511"DATA",1130580001.101,75,1)
    15221512Cervical Cancer Screening
     
    15301520more Pap tests to screen for cervical cancer
    15311521"DATA",1130580001.101,75,7)
    1532 NQF0032^^^^
     1522NQF0032
    15331523"DATA",1130580001.101,76,0)
    1534 MU EP NQF 0033^^
     1524MU EP NQF 0033
    15351525"DATA",1130580001.101,76,1)
    15361526Chlamydia Screening for Women
     
    15461536year.
    15471537"DATA",1130580001.101,76,7)
    1548 NQF0033^^^^
     1538NQF0033
    15491539"DATA",1130580001.101,77,0)
    1550 MU EP NQF 0036^^
     1540MU EP NQF 0036
    15511541"DATA",1130580001.101,77,1)
    15521542Use of Appropriate Medications for Asthma
     
    15641554years, and total).
    15651555"DATA",1130580001.101,77,7)
    1566 NQF0036^^^^
     1556NQF0036
    15671557"DATA",1130580001.101,78,0)
    1568 MU EP NQF 0052^^
     1558MU EP NQF 0052
    15691559"DATA",1130580001.101,78,1)
    15701560Low Back Pain: Use of Imaging Studies
     
    15801570days of diagnosis.
    15811571"DATA",1130580001.101,78,7)
    1582 NQF0052^^^^
     1572NQF0052
    15831573"DATA",1130580001.101,79,0)
    1584 MU EP NQF 0075^^
     1574MU EP NQF 0075
    15851575"DATA",1130580001.101,79,1)
    15861576Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
     
    16041594performed during the measurement year and whose LDL-C<100 mg/dL
    16051595"DATA",1130580001.101,79,7)
    1606 NQF0075^^^^
     1596NQF0075
    16071597"DATA",1130580001.101,80,0)
    1608 MU EP NQF 0575^^
     1598MU EP NQF 0575
    16091599"DATA",1130580001.101,80,1)
    16101600Diabetes:  Hemoglobin A1c Control (<8.0%)
     
    16181608(type 1 or type 2) who had hemoglobin A1c <8.0%
    16191609"DATA",1130580001.101,80,7)
    1620 NQF0575^^^^
     1610NQF0575
    16211611"DATA",1130580001.101,81,0)
    1622 MU EP NQF 0028B^^
     1612MU EP NQF 0028B
    16231613"DATA",1130580001.101,81,1)
    16241614NQF0028B Preventive Care and Screening  Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
     
    16661656NQF0024 2-10Y^^^^^^334^338
    16671657"DATA",1130580001.101,83,0)
    1668 MU EP NQF 0038 NUM1 DPT^^
     1658MU EP NQF 0038 NUM1 DPT
    16691659"DATA",1130580001.101,83,5)
    16701660NQF0038 NUM1 DPT
     
    16721662NQF0038 NUM1 DPT^^^^^^329^192^11
    16731663"DATA",1130580001.101,84,0)
    1674 MU EP NQF 0038 NUM2 IPV^^
     1664MU EP NQF 0038 NUM2 IPV
    16751665"DATA",1130580001.101,84,5)
    16761666NQF0038 NUM2 IPV
     
    16781668NQF0038 NUM2 IPV^^^^^^224^192^11
    16791669"DATA",1130580001.101,85,0)
    1680 MU EP NQF 0038 NUM3 MMR^^
     1670MU EP NQF 0038 NUM3 MMR
    16811671"DATA",1130580001.101,85,5)
    16821672NQF0038 NUM3 MMR
     
    16841674NQF0038 NUM3 MMR^^^^^^183^192^11
    16851675"DATA",1130580001.101,86,0)
    1686 MU EP NQF 0038 NUM4 HiB^^
     1676MU EP NQF 0038 NUM4 HiB
    16871677"DATA",1130580001.101,86,5)
    16881678NQF0038 NUM4 HiB
     
    16901680NQF0038 NUM4 HiB^^^^^^189^192^11
    16911681"DATA",1130580001.101,87,0)
    1692 MU EP NQF 0038 NUM5 HEP B^^
     1682MU EP NQF 0038 NUM5 HEP B
    16931683"DATA",1130580001.101,87,5)
    16941684NQF0038 NUM5 HEP B
     
    16961686NQF0038 NUM5 HEP B^^^^^^194^192^11
    16971687"DATA",1130580001.101,88,0)
    1698 MU EP NQF 0038 NUM6 VZV^^
     1688MU EP NQF 0038 NUM6 VZV
    16991689"DATA",1130580001.101,88,5)
    17001690NQF0038 NUM6 VZV
     
    17021692NQF0038 NUM6 VZV^^^^^^198^192^11
    17031693"DATA",1130580001.101,89,0)
    1704 MU EP NQF 0038 NUM7 PCV^^
     1694MU EP NQF 0038 NUM7 PCV
    17051695"DATA",1130580001.101,89,5)
    17061696NQF0038 NUM7 PCV
     
    17081698NQF0038 NUM7 PCV^^^^^^205^192^11
    17091699"DATA",1130580001.101,90,0)
    1710 MU EP NQF 0038 NUM8 HEP A^^
     1700MU EP NQF 0038 NUM8 HEP A
    17111701"DATA",1130580001.101,90,5)
    17121702NQF0038 NUM8 HEP A
     
    17141704NQF0038 NUM8 HEP A^^^^^^208^192^11
    17151705"DATA",1130580001.101,91,0)
    1716 MU EP NQF 0038 NUM9 RV^^
     1706MU EP NQF 0038 NUM9 RV
    17171707"DATA",1130580001.101,91,5)
    17181708NQF0038 NUM9
     
    17201710NQF0038 NUM9^^^^^^216^192^11
    17211711"DATA",1130580001.101,92,0)
    1722 MU EP NQF 0038 NUM10 FLU^^
     1712MU EP NQF 0038 NUM10 FLU
    17231713"DATA",1130580001.101,92,5)
    17241714NQF0038 NUM10
     
    17261716NQF0038 NUM10^^^^^^331^192^11
    17271717"DATA",1130580001.101,93,0)
    1728 MU EP NQF 0038 NUM11 COMBO5^^
     1718MU EP NQF 0038 NUM11 COMBO5
    17291719"DATA",1130580001.101,93,5)
    17301720NQF0038 NUM11 COMBO5
     
    17321722NQF0038 NUM11 COMBO5^^^^^^228^192^11
    17331723"DATA",1130580001.101,94,0)
    1734 MU EP NQF 0038 NUM12 COMBO6^^
     1724MU EP NQF 0038 NUM12 COMBO6
    17351725"DATA",1130580001.101,94,5)
    17361726NQF0038 NUM12 COMBO6
     
    17381728NQF0038 NUM12 COMBO6^^^^^^231^192^11
    17391729"DATA",1130580001.101,95,0)
    1740 MU 2011 INP ADV DIRECTIVES^^
     1730MU 2011 INP ADV DIRECTIVES
    17411731"DATA",1130580001.101,95,5)
    17421732Advance Directives
    1743 "DATA",1130580001.101,95,7)
    1744 ^^^^
    17451733"DATA",1130580001.101,96,0)
    1746 MU 2011 INP CPOE^^
     1734MU 2011 INP CPOE
    17471735"DATA",1130580001.101,96,5)
    17481736CPOE for Medications
    1749 "DATA",1130580001.101,96,7)
    1750 ^^^^
    17511737"DATA",1130580001.101,97,0)
    1752 MU 2011 INP MED RECON^^
     1738MU 2011 INP MED RECON
    17531739"DATA",1130580001.101,97,5)
    17541740Medication Reconcilliation
    1755 "DATA",1130580001.101,97,7)
    1756 ^^^^
    17571741"DATA",1130580001.101,98,0)
    1758 MU 2011 INP PROBLEM LIST^^
     1742MU 2011 INP PROBLEM LIST
    17591743"DATA",1130580001.101,98,5)
    17601744Problem List
    1761 "DATA",1130580001.101,98,7)
    1762 ^^^^
    17631745"DATA",1130580001.101,99,0)
    1764 MU 2011 INP VITAL SIGNS^^
     1746MU 2011 INP VITAL SIGNS
    17651747"DATA",1130580001.101,99,5)
    17661748Record Vital Signs
    1767 "DATA",1130580001.101,99,7)
    1768 ^^^^
    17691749"DATA",1130580001.101,100,0)
    1770 MU 2011 INP SMOKING STATUS^^
     1750MU 2011 INP SMOKING STATUS
    17711751"DATA",1130580001.101,100,5)
    17721752Smoking Status
    1773 "DATA",1130580001.101,100,7)
    1774 ^^^^
    17751753"DATA",1130580001.101,101,0)
    1776 MU 2011 INP MED LIST^^
     1754MU 2011 INP MED LIST
    17771755"DATA",1130580001.101,101,5)
    17781756Active Medication List
    1779 "DATA",1130580001.101,101,7)
    1780 ^^^^
    17811757"DATA",1130580001.101,102,0)
    1782 MU 2011 INP ALLERGY LIST^^
     1758MU 2011 INP ALLERGY LIST
    17831759"DATA",1130580001.101,102,5)
    17841760Medication Allergy List
    1785 "DATA",1130580001.101,102,7)
    1786 ^^^^
    17871761"DATA",1130580001.101,103,0)
    1788 MU 2011 INP DEMOGRAPHICS^^
     1762MU 2011 INP DEMOGRAPHICS
    17891763"DATA",1130580001.101,103,5)
    17901764Record Demographics
    1791 "DATA",1130580001.101,103,7)
    1792 ^^^^
    17931765"DATA",1130580001.101,104,0)
    17941766MU EP NQF 0024 11-17Y
     
    25452517"FRV1K",1130580001.101,"94,7",9,1)
    25462518MU NQF0038 CHILDREN'S IMMUNIZATIONS
     2519"IX",1130580001.101,1130580001.101,"B",0)
     25201130580001.101^B^New-Style B Index. Will be used as part of the key.^R^^F^IR^I^1130580001.101^^^^^LS
     2521"IX",1130580001.101,1130580001.101,"B",1)
     2522S ^C0Q(101,"B",$E(X,1,30),DA)=""
     2523"IX",1130580001.101,1130580001.101,"B",2)
     2524K ^C0Q(101,"B",$E(X,1,30),DA)
     2525"IX",1130580001.101,1130580001.101,"B",2.5)
     2526K ^C0Q(101,"B")
     2527"IX",1130580001.101,1130580001.101,"B",11.1,0)
     2528^.114IA^1^1
     2529"IX",1130580001.101,1130580001.101,"B",11.1,1,0)
     25301^F^1130580001.101^.01^30^1^F
    25472531"IX",1130580001.101,1130580001.101,"MU",0)
    254825321130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
     
    25572541"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
    255825421^F^1130580001.101^.3^30^1^F
     2543"KEY",1130580001.101,1130580001.101,"A",0)
     25441130580001.101^A^P^562
     2545"KEY",1130580001.101,1130580001.101,"A",2,0)
     2546^.312IA^1^1
     2547"KEY",1130580001.101,1130580001.101,"A",2,1,0)
     2548.01^1130580001.101^1
     2549"KEYPTR",1130580001.101,1130580001.101,"A")
     25501130580001.101^B
    25592551"MBREQ")
    256025520
     
    25862578^9.49I^1^1
    25872579"PKG",215,22,1,0)
    2588 1.0^3120731^3120802^8
     25801.0^3120731^3120806^8
    25892581"PKG",215,22,1,"PAH",1,0)
    2590 3^3120803
     25823^3120806^8
    25912583"PKG",215,22,1,"PAH",1,1,0)
    2592 ^^155^155^3120803
     2584^^155^155^3120806
    25932585"PKG",215,22,1,"PAH",1,1,1,0)
    25942586 Summary
     
    30022994
    30032995"^DD",1130580001.101,1130580001.101,0,"VRPK")
    3004 QUALITY MEASURES
     2996C0Q
    30052997"^DD",1130580001.101,1130580001.101,.01,0)
    30062998NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
Note: See TracChangeset for help on using the changeset viewer.